GLP-1s Set to Top $100 Billion in Obesity
Groundbreaking Insights on GLP-1 Medications and Their Impact
In this episode of The Downsized News, hosts Laraine and Christopher Durham discuss intriguing new research that reveals how popular weight loss medications suppress appetite and enhance metabolism. Key studies led by Professor Donal O'Shea show that GLP-1 drugs like Zepbound, Mounjaro, Ozempic and Wegovy significantly boost metabolic rates and promote weight loss. Major pharmaceutical companies Eli Lilly and Novo Nordisk dominate the lucrative GLP-1 market, with their drugs showing substantial growth. New players like Palatin Technologies are also entering the scene with promising clinical trials. The episode also addresses concerns about potential links between semaglutide and suicidal ideation while emphasizing the importance of consulting healthcare professionals for personalized treatment. Join the Downsized community for more updates, insights, and live interactions.
BECOME A DOWNSIZED MEMBER: https://www.youtube.com/@thedownsized...
DOWNSIZED GLP-1 COMPANION PRODUCT STORE: https://thedownsized.org/downsized-st...
Start your weight loss journey today! We use Mochi Health: https://joinmochi.com/. Use Laraine’s code for $40 off: QIYGO8.
DOWNSIZED WEBSITE: https://thedownsized.org/
00:00 Introduction to GLP-1 News
00:21 Understanding GLP-1 Medications
01:04 New Study on Metabolism and Weight Loss
03:17 Market Competition Among GLP-1 Drugs
09:20 Debate on Suicidal Ideation and GLP-1
13:33 New Developments in Obesity Treatment
16:15 Conclusion and Community Engagement
Watch video GLP-1s Set to Top $100 Billion in Obesity online without registration, duration hours minute second in high quality. This video was added by user DOWNSIZED 26 August 2024, don't forget to share it with your friends and acquaintances, it has been viewed on our site 1,40 once and liked it 16 people.